¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º CP'-CQ\Q  
H:_`]X"  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ @e7+d@ O<  
21[F%,{.),  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) ?xet:#R'  
3:( `#YY  
1. ICAM-1 meWAm?8RI  
9wC; m:  
2. interleukin 12(IL-12) Sf8d|R@O  
rBf?kDt6l  
3. tumor infiltrating lymphocyte MlZ`g,{  
2YyZiOMSc  
4. TCR/CD3 complex NP8TF*5V  
GpL#, qYc  
5. hematopoietin receptor family ]YP?bP,:  
pA'A<|)K0  
6. individual idiotype(IdI) 4lA+V, #  
P `"7m-  
7. integrin F0Hbklr  
Qx;A; n!lw  
8. colony-stimulatory factor (CSF) e`r;`a&  
a"}#HvB+  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ]B4mm__  
L])w-  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? @3YuV=QfH  
Gq/6{eRo\  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ rzDJH:W{2  
4-_lf(# i  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷ÓᣠKdu\`c-lB  
v Lv@Mo  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ X vMG09  
Hs=N0Sk]j  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) Z4ioXl  
#Hi]&)p_  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ I^(#\vRW  
NxO^VUD  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) D|j \ nQ  
bs EpET  
3. immunoglobulin superfamily (IgSF) Ir"Q%>K0f  
p''"E$B/(  
4. selectin _G #"B{7  
) Zo_6%  
5. anti-idiotypic antibody (¦ÁId) -MU.Hu  
6\fMzm  
6. major histocompatibility complex(MHC) 5}bZs` C  
l@r wf$-  
7. immunotolerance fTV|? :C{  
{lTxB'W@d  
8. biological reponse modifier(BRM) }?]yxa~  
H9VXsFTW  
9. immune reponse gene (Ir gene) 7k=F6k0)  
]]=fA 4(  
10. reshaped antibody (or reconstituted antibody) hMeqs+  
n<<=sj$\!  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© ? x"HX|n  
N^ s!!Sbpq  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ n5+S"  
@>fO;*  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? 4[#6<Ixf  
kg: uGP9  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ UM( l%  
w^])(  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? %x}&=zx0*1  
g+}s:9  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ |ck ZyDA  
lH)em.#  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? w}j6 .r  
d]CviQUq  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ h41$|lonU%  
m0|Ae@g~3  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ 6Q2or n[  
 ,v*p  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? ?""\  
B;GxfYj  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ mQJ4;BJw  
E kBae=  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: #vj#! 1  
G@!_ZM8h  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: q%-&[%l  
-BA"3 S  
ÃâÒßѧ As@ihB+(\  
^]$$)(jw  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© G{kj}>kS_  
0)d?Y  
1. CD8 _0,"vFdj  
K2cq97k,d  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) rIeM+h7Wn  
ybZ}  
3. immunoglobulin fold(Ig fold) !2}rtDE  
2GSgG.%SSM  
4. cadherin (Ca-dependent cell adhesion moleculers) NW{y% Z  
f.| |P H  
5. idiotype-anti-idiotypic antibody immune network theory 0VzXDb>`  
u3]Uxy  
6. HLA class II antigen 3->,So0Y  
LeY+p]n~  
7. complementarity-determining region (CDR) ^vpIZjN  
5 k69F   
8. perforin(or pore-forming protein ,PFP) 16I&7=S,  
0$tjNy e  
9. high affinity IL-2 receptor 6sPk:5  
8;TAb.r  
10. artificial active immunization #(6) ^ (  
&vCeLh:s  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© Pg/T^n&  
bFg*l$`5  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦Óᣠ: (gZgMT  
MY!q%  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 6O9iEc,HM  
-I ?z-?<D  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ XYe~G@Q Z  
SB TPTb  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ Gzw@w{JBL  
iU5P$7.p  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ }X]\VSF{  
~wOTjz  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? :\b|dvI<  
Lz@$3(2  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ GAw(mH*  
/kB|1gFj  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ EyY],W1 Y  
XE1$K_m  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ M+poB+K.  
%<} <'V0  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ ;~+]! U  
/[ K_ &  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© QXVC\@  
F2;:vTA>  
1. immunoglobulin gene rearrangement T#EFXHPr  
Icx7. Y  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) yK1ie  
gKo%(6{n~  
3. flow cytometry(FCM) ?Go!j?#a  
;3"@g] e  
4. carrier effect 0[xpEiDx  
`Ye8 Q5v"]  
5. positive selection of T lymphocytes in thymus G.\l qYrXU  
PFrfd_s{>\  
6. mouse TH1(Th1) and TH2(Th2) subsets lCIDBBjy^  
!GwL,)0@^  
7. perforin (pore-forming protein ,PFP) $f$|6jM  
< zOi4v0  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) S6xgiem  
DinPxtT?a  
9. SH-2(src-homology region 2) ;H'gT+t<c  
3j Z6kfj  
10. Ab2¦Â (internal image) V}WB*bE  
lg$zG a?  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© k; ZxY"^  
k@dN$O%p  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? +4))/` DA  
r;&>iX4B  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? CGbwm Px  
RY9V~8|M  
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠ>&:NFq-  
Oz: *LZ  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ &;&ho+qD  
{)8>jxQN  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ'' O7=\  
'c ix`l|^  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) **3 z;58 i  
ar9]"s+'  
ÃâÒßѧרҵ£º BZ54*\t  
(xHf 4[[u  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ @a:>$t  
xG&)1sT#-\  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? },+wJ1  
C?Bl{4-P}*  
´«È¾²¡Ñ§×¨Òµ£º aI^/X {d  
Q/>{f0  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ #P l~R  
ydRC1~f0  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ 3b'QLfU&#  
NS%WeAf  
Ïû»¯×¨Òµ£º ^?7` ;/  
)E@A0W  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ &e 6CJ  
?7<JQh)"e  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ?  wr[,  
A C>`'Gx  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ Tb3J9q+ya  
~HOy:1QhE=  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© Y. ,Kl~  
ZovW0Q)m  
1. Fas(CD95)/FasL uV!^,,~  
0T Q$C-%  
2. common chain of cytokine receptor { ^cV lC_  
\v'p/G)g  
3 . TCR/CD3 complex N5a*7EJv+  
c-B cA  
4. negaive selection of thymocytes eeyHy"@  
]H`1F1=  
5. artificial active immune  -i0~]*  
dBz/7&Q   
6. anti-idiotypic H Z'_r cv  
nih0t^m'  
7. IgSF Zl^\Q=*s  
7@D@ucL  
8. Integrin HMSO=)@+  
uScMn/%  
9. chemokine hDF@'G8F  
f|\onHI)>  
10. B7/CD28 RW<D<5C  
>CHrg]9  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© '@_d(N1jTw  
%nf6%@s  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ 1q7|OWFT  
$g> IyT[  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ 3}}38A|4  
_852H$H\  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ '=b/6@&  
Q'=x|K#xj  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ b3=rG(0f  
ofm#'7P 0  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ ,E S0NA  
| )K8N<n  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ ]cHgleHQ  
]_f_w 9]  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© E(>=rD/+  
5_GYrR2  
1. B7/CD28 DX#Nf""Pw  
Sc]B#/~B  
2. Th1 subset fDv2JdiU  
G#ZH.24Y  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© {'7B6  
]E5o1eeg  
4. antibody affinity maturation Ri<u/ ]oR"  
r8`ffH  
5. AP-1 KI"#f$2&  
hNC&T`.-~B  
6. single chain variable fragment£¨ScFv£© S|Q@:r"  
{&&z-^  
7. NK cell receptor g9 .Q<JwO  
Hus)c3Ty7  
8. Zinkernagel-Doherty phenomenon sA+ }TNhq  
]%;:7?5l  
9. Ig fold k R?qb6  
Akq2 d;  
10. CD40/CD40L d-oMQGOklb  
z<MsKD0Q  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© lov!o: dJ  
xB@ T|EP  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ .#EF LXs  
(^ J I%>  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ =7?4eYHC  
zrvF]|1UP  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿ 2IK}vDsis  
ez7A4>/  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ _?nL+\'V  
)j6~Wy@4  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ 11NQR[  
wH*-(*N "  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ T9=I$@/  
_YRFet[,m  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ yNPVOp*  
`>o{P/HN  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© I{|O "8  
{qk1_yP  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© Lj({[H7D!  
x>K Or,f  
1.Co-stimulators (or co-stimulating molecules) cVv=*81\  
\  #F  
2.NK-kB \doUTr R  
E_rI?t^  
3.Immunoglobulin superfamily )_90UwWpj  
 fgTg7 m  
4.antigen-presenting cell (APC) 6q\bB  
M)Z7k/=<P  
5.death domain /xBb[44z8  
6GlJ>r+n  
6.CCR and CXCR g{)dP!}  
#lo6c;*m5  
7.Lectin (or mitogen) `,(4]tlL  
1s&zMWC  
8.Clusters of differentiation, CD) yWc$>ne[L  
`g?Negt\v  
9.B7 family O/(`S<iip  
r|8d 4  
10.Cytotoxic T lymphocyte, CTL) wU36sCo  
_.Nbt(mz  
11.IL-15 and IL-15 receptor (IL-15R) +)om^e@.  
2zA4vZkbcw  
12.MHC restriction >2)OiQ`zg  
{<p?2E  
13.Affinity-chromatography ^/>(6>S^M  
2]jn '4  
14.Cyctosprin A, CsA ^mDe08. %b  
4[r0G+  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) 2WL|wwA  
~$cV: O7  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© %nZo4hnr$r  
A RuA<vQ  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 1CD+B=pQG  
6 7.+ .2  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ {X+3;&@  
%P/Jq#FE .  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ z+wA rPxc  
&j`}vg  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© Id'-&tYG  
rSk >  
ÃâÒßѧרҵ£º W~; `WR;.  
]L $\ #  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ py!|\00}  
`/XY>T}-  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ Xm}/0g&7  
X,_2FJv  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ XGWSdPJLr  
,, OW  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) SCHP L.n  
Tod&&T'UW  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) zuad~%D<I  
3> AMII  
1. ADCC(antibody dependent cell-mediated cytotoxicity) :Zbg9`d*  
wj^3N7_:w  
2. »·æß¾úËØ(cyclosporin) ^A$Zw+P  
^R7lom.  
3. KIR(killer cell inhibitory receptor) :'-/NtV)o?  
Eqd<MY7  
4. HLDA(human leucocyte differentiation antigen) t ;;U}  
v6bGjVK[  
5. Interleukin 18(IL-18) ]?kZni8j_  
g0=z&2Q[_)  
6. ÕûºÏËØ(integrin) |`2RShu  
a`E#F] Z  
7. Fas/FasL @sW24J1q+  
9}!qR|l3nR  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) (&F}/s gbi  
pk$l+sNZ=  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) s 8jV(P(O  
BDW^7[n  
10. Th1/Th2 y1eW pPJa  
<e=#F-DE  
11. »ùÒòÒßÃç(DNAÒßÃç) {0Yf]FQb-a  
JW83Tp8[8  
12. chemokines and chemokine receptor %op**@4/t\  
/ |;RV"  
13. ÃâÒßÄÍÊÜ %A9NB!  
0y'H~(  
14. ¹²´Ì¼¤·Ö×Ó z1 | TC  
?4#Li~q  
15. ËÀÍö½á¹¹Óò(death domain) G#q@v(_b  
i4Q@K,$  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) 5,lEx1{_  
*MFIV02[N  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? ,hm\   
$u6"*|  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠ[B*x-R[FI  
'5#^i:  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î aB2F C$z  
g-4M3of  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ J\} twYty  
3)t.p>VgO  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå EqkN3%IG  
r..iko]T  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ u"r`3P`  
-lr vKrt7  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) )` SrfGp8  
jodIv=C  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ G=s}12/Z"{  
M!siK2  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ :_ `F{rDB  
i<C*j4qQ  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»